{"filing":{"accession_number":"0001437749-26-033323","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-31","primary_document":"athe20261023d_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926033323/athe20261023d_6k.htm"},"events":[{"id":37391,"run_id":34468,"accession_number":"0001437749-26-033323","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"summary":"The 6-K references Exhibit 99.1 titled \"Proposed issue of securities - ATH,\" indicating a planned equity issuance by Alterity Therapeutics. Although the exhibit itself is not furnished in the body, the cover page explicitly lists this as the subject matter being submitted. For a development-stage biotech company, a securities issuance is typically material to investors assessing capital structure and dilution risk.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":42088,"accession_number":"0001437749-26-033323","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The 6-K references Exhibit 99.1 titled \"Proposed issue of securities - ATH,\" indicating a planned equity issuance by Alterity Therapeutics. Although the exhibit itself is not furnished in the body, the cover page explicitly lists this as the subject matter being submitted. For a development-stage biotech company, a securities issuance is typically material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:06:15.188383+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-10-23"}]}